02.16.12
Evotec AG and IR Pharma have entered into an exclusive strategic alliance to provide integrated drug discovery solutions in the field of respiratory diseases. Financial terms were not disclosed.
The alliance expands Evotec's drug discovery platform into the area of respiratory diseases through IR Pharma's expertise in in vitro and in vivo respiratory pharmacology. Also, Evotec is now able to offer fully integrated respiratory and inflammation focused drug discovery programs, from target to nomination of preclinical development candidates.
Mario Polywka, chief operating officer at Evotec AG, said, "We are looking forward to partnering with IR Pharma and are excited about the potential of this alliance. IR Pharma has outstanding expertise in the respiratory disease area including disease relevant in vivo models and coupled with our world leading discovery engine and commercial reach, we are sure we can bring outstanding value to existing and future partners and collaborators in these demanding disease areas. This co-operation is a significant addition to our strategy to offer the most comprehensive drug discovery solutions to our partners."
Maria Belvisi, director at IR Pharma, said, "We are delighted to join forces with Evotec and firmly believe that together, we will provide efficient and innovative drug discovery solutions to our partners. We have a range of highly validated models, focusing on Asthma, Cough and Chronic Obstructive Pulmonary Disease (COPD), which ideally complement Evotec's platform, thus enabling a fully integrated approach to drug discovery in this challenging area."
The alliance expands Evotec's drug discovery platform into the area of respiratory diseases through IR Pharma's expertise in in vitro and in vivo respiratory pharmacology. Also, Evotec is now able to offer fully integrated respiratory and inflammation focused drug discovery programs, from target to nomination of preclinical development candidates.
Mario Polywka, chief operating officer at Evotec AG, said, "We are looking forward to partnering with IR Pharma and are excited about the potential of this alliance. IR Pharma has outstanding expertise in the respiratory disease area including disease relevant in vivo models and coupled with our world leading discovery engine and commercial reach, we are sure we can bring outstanding value to existing and future partners and collaborators in these demanding disease areas. This co-operation is a significant addition to our strategy to offer the most comprehensive drug discovery solutions to our partners."
Maria Belvisi, director at IR Pharma, said, "We are delighted to join forces with Evotec and firmly believe that together, we will provide efficient and innovative drug discovery solutions to our partners. We have a range of highly validated models, focusing on Asthma, Cough and Chronic Obstructive Pulmonary Disease (COPD), which ideally complement Evotec's platform, thus enabling a fully integrated approach to drug discovery in this challenging area."